Subsequent investigations revealed that ALYREF promotes platinum resistance in ovarian cancer cells by activating the Wnt/β-Catenin pathway via the NSUN2/ALYREF/LGR4 signaling axis. The gene discussed is ALYREF; the disease is ovarian cancer.